These findings suggested that there were possible mechanism-specific protective effects of statins (targeting HMG-CoA reductase) and ezetimibe (targeting NPC1L1) on breast cancer, whereas PCSK9 inhibitors might have protective effect on prostate cancer. The gene discussed is NPC1L1; the disease is Familial prostate cancer.